Comparative Pharmacology
Head-to-head clinical analysis: ENDURONYL FORTE versus TRICHLOREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDURONYL FORTE versus TRICHLOREX.
ENDURONYL FORTE vs TRICHLOREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enduronyl Forte is a combination of methyclothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, and deserpidine, a Rauwolfia alkaloid that depletes catecholamines from adrenergic nerve endings, resulting in reduced peripheral vascular resistance and CNS sedation.
Trichlorex is a thiazide-like diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing water excretion.
Oral: Initial 2.5-5 mg once daily; increase as needed to maximum 20 mg once daily.
Oral: 500 mg once daily after the evening meal; sustained-release: 500 mg once daily at bedtime.
None Documented
None Documented
Terminal elimination half-life: 24-48 hours (avg. 36 h); due to long half-life, requires caution in renal impairment.
Terminal elimination half-life is 8-12 hours in adults; prolonged to 20-30 hours in severe renal impairment (creatinine clearance <30 mL/min).
Renal: ~50% unchanged; Biliary/Fecal: ~50% as metabolites and unchanged drug.
Renal (90% as unchanged drug, 10% as trichloroacetic acid and trichloroethanol); minor biliary/fecal (less than 1%).
Category C
Category C
Thiazide Diuretic + Rauwolfia Alkaloid
Thiazide Diuretic